CONMED Corporation — Q1 2015 Form 10-Q Summary
Business context and reporting period
CONMED is a global medical technology company providing surgical devices and equipment for minimally invasive procedures, serving orthopedic, general surgery, gynecology, neurosurgery and gastroenterology markets. The filing covers the three months ended March 31, 2015; financial statements are unaudited. Approximately 79% of revenue came from single-use products and international sales represented approximately 51.1% of revenue.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Net sales | $177.9 million | $181.9 million | Down 2.2% |
| Gross profit | $92.3 million | $102.6 million | Down 10.0% |
| Gross margin | 51.9% | 56.4% | Down 4.5 percentage points |
| Income from operations | $11.0 million | $17.3 million | Down 36.7% |
| Operating margin | 6.2% | 9.5% | Down 3.3 percentage points |
| Net income | $6.3 million | $8.6 million | Down 26.8% |
| Diluted EPS | $0.23 | $0.31 | Down $0.08 |
| Operating cash flow | $14.8 million | $17.0 million | Down $2.2 million |
Product-line sales were $98.6 million for orthopedic surgery, $66.1 million for general surgery and $13.3 million for surgical visualization. Capital equipment sales increased 6.5% to $37.8 million, while single-use product sales decreased 4.3% to $140.1 million.
At March 31, 2015, cash and cash equivalents were $65.7 million, working capital was $260.6 million and total debt was approximately $258.4 million, including $252.0 million outstanding under the revolving credit facility and a $6.4 million mortgage note. Revolving-facility availability was $92.6 million, with approximately $5.4 million reserved for letters of credit. The company was in compliance with its debt covenants.
Material changes versus the prior comparable period
- Revenue declined primarily because orthopedic surgery sales fell 6.9% to $98.6 million. General surgery increased 4.1% and surgical visualization increased 5.6%.
- In constant currency, excluding the effects of the hedging program, consolidated sales increased 0.8%; reported results were adversely affected by foreign exchange.
- Gross margin declined because of unfavorable production variances, foreign exchange effects, higher restructuring costs and product mix.
- Selling and administrative expense declined 4.6% to $74.8 million, reflecting prior restructuring, lower medical device tax and lower legal costs than in Q1 2014.
- The effective tax rate decreased to 33.5% from 45.6%. The prior-year rate included a $2.3 million non-cash write-off of New York State deferred tax assets following tax legislation changes.
- Operating cash flow decreased despite lower inventory balances, primarily reflecting lower earnings and working-capital movements.
- Financing cash use improved to $4.6 million from $11.2 million, as the company made no share repurchases in Q1 2015 compared with $16.9 million in Q1 2014.
Guidance, outlook, risks and unusual items
- Management expects approximately $16.0 million of capital expenditures in 2015.
- Remaining restructuring costs are estimated at approximately $4.0 million to $6.0 million, net of tax, for the remainder of 2015. The Centennial, Colorado manufacturing consolidation is expected to be completed within approximately nine months, with anticipated annual cost-of-sales savings of $3.5 million to $4.5 million after completion.
- The company expects to fund the remaining $16.7 million payment under its MTF distribution and development agreement through cash on hand and available revolver capacity. EndoDynamix contingent consideration remaining at March 31, 2015 was $10.2 million; a $2.4 million milestone payment was made on April 13, 2015.
- Comprehensive loss was $3.7 million, compared with comprehensive income of $9.6 million in Q1 2014, primarily because of a $12.5 million foreign-currency translation loss.
- Foreign-exchange forward contracts designated as cash-flow hedges had $77.8 million of notional amounts outstanding and $5.2 million of net unrealized gains included in accumulated other comprehensive loss.
- The Centennial facility remains subject to FDA-related remediation. The FDA issued a 2014 Form 483 containing eight observations, including three repeat observations; the company was responding to additional FDA questions. Future inspections could result in further regulatory action, including a warning letter, consent decree or fines.
- Key disclosed risks include foreign exchange, competition, product acceptance, acquisitions, material costs, regulatory compliance, product liability, patent litigation, allograft tissue availability, indebtedness and customer purchasing patterns. Management provided no specific full-year revenue or earnings guidance in the filing.
Important facts for investors to verify
- Whether orthopedic surgery sales stabilize and whether general surgery and visualization growth continues to offset weakness in orthopedic products.
- The timing and total cost of the Centennial consolidation and whether the projected $3.5 million to $4.5 million annual savings are achieved.
- Progress on FDA remediation and any subsequent inspection findings or enforcement actions.
- Revolver utilization, covenant headroom and the company’s ability to fund the $16.7 million MTF payment, EndoDynamix obligations, capital expenditures and dividends.
- The effect of foreign-exchange movements and hedging on reported revenue, gross margin and comprehensive income.
- The remaining $37.4 million authorization under the share repurchase program and whether future repurchases are resumed.